What is the Homeostatic Model Assessment of β‑cell function (HOMA‑β) and how is it used in clinical practice?

What is HOMA-β?

HOMA-β (Homeostatic Model Assessment of β-cell function) is a mathematical calculation that estimates pancreatic β-cell insulin secretory function using fasting glucose and insulin levels, calculated as: (20 × fasting insulin [μU/mL]) / (fasting glucose [mmol/L] - 3.5) × 100% 1.

Understanding the Calculation

HOMA-β provides a simple, inexpensive surrogate measure of β-cell function without requiring complex dynamic testing. The formula assumes a feedback loop between glucose and insulin under fasting (basal) conditions 1. Normal values typically range above 100%, with lower values indicating progressive β-cell dysfunction.

Clinical Applications in Practice

1. Predicting Need for Insulin Therapy in Type 2 Diabetes

When HOMA-β falls below approximately 20-25%, patients with type 2 diabetes typically require insulin therapy 2. In a prospective study, patients requiring insulin had mean HOMA-β of 19.4% compared to 24.5% in those responding to triple oral therapy 2. This provides an objective threshold for escalating treatment beyond oral agents.

2. Cardiovascular Risk Stratification

In non-diabetic patients with cardiovascular disease, HOMA-β ≤49.3% identifies those at 2.65-fold increased risk for adverse cardiovascular events 3. This recent 2025 study demonstrates that reduced insulin secretion capacity predicts mortality, myocardial infarction, and heart failure even in the absence of diabetes 3. Adding HOMA-β to traditional risk factors (age, sex, eGFR, ejection fraction) significantly improves risk prediction.

3. Specialized Diagnostic Use

For insulinoma diagnosis, HOMA-β >253 (using insulin) or >270 (using C-peptide) at the end of a 72-hour fasting test provides sensitivity of 0.96 and specificity ≥0.96, potentially serving as an alternative to glucagon stimulation testing 4.

Important Caveats and Limitations

Critical Mathematical Assumptions

Recent 2024 evidence demonstrates that HOMA-β and other β-cell function indices can produce contradictory results that don't reflect actual insulin secretion-glucose relationships 5. The index relies on mathematical assumptions about the feedback loop that may not hold across different metabolic states. When comparing lean individuals with normal glucose tolerance to various obesity/diabetes groups, index-based assessments contradicted the actual observed insulin secretion patterns 5.

When HOMA-β Works Best

• Fasting state only: HOMA-β reflects basal β-cell function, not dynamic insulin secretion capacity
• Population comparisons: More reliable for group-level differences than individual clinical decisions
• Serial monitoring: Tracking changes within the same patient over time is more valid than single measurements
• Stable metabolic conditions: Acute illness, medications affecting glucose/insulin, and recent meals invalidate results

When to Be Cautious

• Do not use HOMA-β as the sole criterion for major treatment decisions without considering clinical context
• Values are affected by insulin resistance (which HOMA-β doesn't fully account for despite the name)
• Different laboratories and insulin assays produce different values—establish local reference ranges
• The index performs poorly in type 1 diabetes or severe β-cell failure where fasting insulin is minimal

Practical Clinical Algorithm

For Type 2 Diabetes Management:

1. Calculate HOMA-β when considering treatment intensification in patients failing oral agents
2. If HOMA-β <20-25% → strongly consider insulin initiation
3. If HOMA-β 25-50% → trial additional oral agents or GLP-1 agonists reasonable
4. If HOMA-β >50% → focus on insulin resistance with metformin, lifestyle, or insulin sensitizers

For Cardiovascular Risk Assessment:

1. In non-diabetic CVD patients, calculate HOMA-β at baseline
2. If ≤49.3% → intensify cardiovascular risk reduction strategies and closer monitoring
3. Consider this an independent risk marker beyond traditional factors 3

The Bottom Line

While HOMA-β provides useful information about β-cell function in specific contexts—particularly predicting insulin requirements in type 2 diabetes 2 and cardiovascular risk stratification 3—it should supplement rather than replace clinical judgment. The 2022 AACE guidelines emphasize that type 2 diabetes involves "progressive loss of β-cell insulin secretion" 6, and HOMA-β offers one quantitative window into this process, but recent evidence highlights significant limitations in how accurately indices capture true β-cell function 5.